Europe’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the approval of Orserdu (elacestrant) monotherapy for treating postmenopausal women and men with oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have experienced disease progression following one ...